Press releases

You are here

Home    /    News    /    Press releases
2019
2019/07Amoéba announces the issuance of the 7th tranche of 26 bonds convertible into shares
2019/07Amoéba announces the possible use of its substance for the treatment of one of the pathogens of field crops
2019/06Descriptif du programme de rachat d'actions autorisé par l'assemblée générale du 20 juin 2019
2019/06Changes in the composition of Amoeba's Board of Directors
2019/06Amoéba announces the issuance of the 6th tranche of 26 bonds convertible into shares
2019/06Amoéba announces that the decision of the US EPA is expected at the end of August 2019
2019/06Availability of the preparatory documents to the general meeting of june 20, 2019
2019/05Amoéba announces the issuance of the fifth tranche of 26 bonds convertible into shares
2019/04Amoéba announces the availability of its 2018 Registration Document
2019/04Amoéba announces the issuance of the fourth tranche of 26 bonds convertible into shares
2019/03Amoéba announces that the dossier for its biocidal active substance approval is still under scientific review by the US EPA
2019/032018 annual results in line with the company's repositioning
2019/03Amoéba announces the issuance of the third tranche of 26 bonds convertible into shares
2019/03Amoéba announces that its active substance has an eliciting action on the vine and a direct action on the germination of grape downy mildew
2019/02Amoéba announces that Malta has agreed to be the reviewer of the new application for approval of its active substance for biocidal application in Europe
2019/02Amoéba announces the issuance of the second tranche of 26 bonds convertible into shares
2019/02Amoéba announces that Austria has accepted to be the Rapporteur Member state to start the evaluation of its biocontrol active substance in Europe in the first quarter of 2020 with a view to a potential commercialisation in 2025
2019/02Amoéba announces a major scientific advance of the formulation of its amoeba Willaertia magna C2c Maky intended for plant protection
2019/02Amoéba informs on the status of the applications for registration of its biocidal product in the United States and Canada
2019/01Amoéba announces the issuance of 26 bonds convertible into shares as part of its bond financing
2019/01Half year review of the liquidity contract on 31st december 2018 
2018
2018/12Availability of preparatory documents for the shareholders' general meeting on january 14th 2019
2018/12Amoéba announces the approval by the AMF of the operation note relating to the OCAPI financing program and informs about the development status of the various applications and the next regulatory deadlines
2018/12Amoéba announces the signature of an amendment to the financing contract (OCAPI) and a subordination agreement
2018/11Amoéba announces the result of the European vote on the non-approval and informs on the medium term prospect of submitting an updated dossier.
2018/11Results of a safety and efficacy study assessing the fate of Legionella Pneumophila in Willaertia magna C2c Maky.
2018/092018 interim financial report
2018/09The Board of Directors nominates Bernard AMBOLET as new independant Director
2018/092018 half year results impacted by the company repositioning
2018/09Amoéba announces that it has reached the last phase of the assessment for its regulatory dossier in the united States
2018/07Amoéba announces the establishment of a € 6 million bond financing line
2018/07Amoéba and Earthwise announce positive efficacy results for the first field test in the U.S.A.
2018/07Half-Year review of the lliquidity contract
2018/06Descriptif du programme de rachat d'actions - Assemblée Générale 21 juin 2018 (In French only)
2018/06Availability of preparatory documents for the annual General Meeting on 21st June 2018
2018/06Amoéba informs of the release of the Biocidal Products Committee opinion
2018/05Amoéba announces its plan of restructuring
2018/05Amoéba announces efficacy results of more than 90% for Willaertia magna C2c Maky on vine mildew 
2018/04Amoéba informs of the adoption by the Biocidal Product Committee of the non-approval o the active substance
2018/04Amoéba confirms the European regulatory stages
2018/032017 full-year results in line with development plan
2018/01Half-year review of the liquidity contract on 31st december 2017
2017
2017/11AMOEBA et CONIDIA validate the effect of Willaertia Magna as a biocontrol agent for the prevention of plant diseases
2017/11AMOEBA signs a Letter of Intent with H2O FACILITIES
2017/10European Investment Bank (EIB) provides EUR 20m credit line to Amoéba to revolutionise water treatment 
2017/092017 Interim Financial Report
2017/092017 half-year results in line with the Group's expectations
2017/09AMOEBA signs a distribution agreement with DREWO
2017/09AMOEBA communicates about European Working Group held on its regulatory dossier
2017/07AMOEBA signs a Letter of Intent with MOMAR
2017/07Half-year review of the liquidity contract on 30th June 2017
2017/06AMOEBA and VISCUS BIOLOGICS announe a joint program for the treatment of multi-resistant bacteria for human wound care 
2017/06Descriptif du programme de rachat d'actions - Assemblée Générale 22 juin 2017 (In French only)
2017/06Availability of preparatory documents for the annual General Meeting on 22nd June 2017
2017/05AMOEBA signs first distribution agreement in the USA with EARTHWISE
2017/05NOVOCHEM signs a distribution agreement for the Benelux 
2017/05AMOEBA signs a Letter of Intent for the distribution of BIOMEBA in Romania
2017/04AMOEBA announces the publication of its registration document for the 2016 period
2017/032016 full-year results in line with development plan
2017/03AMOEBA announces receipt of the evaluation report from the French competent authority, ANSES
2017/03Arnaud MERIENNE appointed General Manager of AMOEBA
2017/02AMOEBA to start R&D tests in the USA
2017/02AMOEBA signs a Letter of Intent with KROFF CHEMICAL COMPANY
2017/01AMOEBA extends the protection of its technology in France and China
2017/01AMOEBA signs a Letter of Intent with GARRATT-CALLAHAN
2017/01AMOEBA extends its commercial network in Italy : signature of a LOI with NCR Biochemical
2017/01Half-year review of the liquidity contract on 31st december 2016
2016
2016/12AMOEBA announces update of the regulatory calendar in the United States of America
2016/12AMOEBA extends its commercial cover with the signature of a new letter of intent with OXIDINE to distribute BIOMEBA in Spain
2016/12AMOEBA confirms the submission of its comments to the French regulatory authority
2016/11AMOEBA announces receipt of the first draft of the regulatory evaluation report
2016/10AMOEBA inaugurates its first industrial site in Lyon - Chassieu
2016/09AMOEBA obtains Marketing Authorisation for R&D purposes for 10 industrial sites in Spain
2016/09AMOEBA granted Marketing Authorisation for R&D for 10 industrial sites in Germany
2016/09Interim financial report 2016
2016/09A Letter of Intent signed with AQUA-SERV in the United States for the distribution of BIOMEBA in three New States
2016/09A new Letter of Intent signed with GREEN Chemicals in Brazil
2016/07Extension to AMOEBA's portfolio of patents in Japan and Europe
2016/07Half-year review of the liquidity contract on 30 June 2016
2016/06Descriptif du programme de rachat d'actions  - Assemblée Générale du 22 juin 2016 (In French only)
2016/06Update to provisional MA schedule
2016/06Availability of preparatory documents for the annual General Meeting on 22nd June 2016
2016/06Information relating to the number of shares and voting rights following a capital increase
2016/05AMOEBA raises EUR 14,693,805 million from European and US investors
2016/0529 April 2016: Monitoring council nominates Mrs Gaëtane Suzenet as new independent member
2016/04AMOEBA announces publication of its registration document for the 2015 period
2016/04AMOEBA obtains market approval for R&D purposes for 10 industrial sites each in Belgium, Italy and the Netherlands
2016/04AMOEBA extends protection of its technology to Russia and the USA
2016/04AMOEBA announces its participation in the EUROPEAN SMALLCAP EVENT on 11 and 12 April 2016 in Paris
2016/03Full-year 2015 results online with the development plan
2016/03First launch planned on the Turkish market. signature of a letter of intent with GREEN Chemicals
2016/02AMOEBA to gain access to the European market as soon as its solution is validated by ANSES
2016/02AMOEBA extends its portfolio of patents in Europe and in the United States
2016/02Financial communications calendar 2016
2016/01AMOEBA extends its commercial coverage to Poland
2016/01Half-year review of the liquidity contract
2015
2014
2013
2012
2011
2010